Skip to main content
Top
Published in: Current Pain and Headache Reports 1/2012

01-02-2012 | Anesthetic Techniques in Pain Management (GJ Brenner, Section editor)

Contemporary Insights into Painful Diabetic Neuropathy and Treatment with Spinal Cord Stimulation

Authors: Kai McGreevy, Kayode A. Williams

Published in: Current Pain and Headache Reports | Issue 1/2012

Login to get access

Abstract

A substantial body of literature is available on the natural history of diabetes, but much less is understood of the natural history of painful diabetic peripheral neuropathy (PDPN), a pervasive and costly complication of diabetes mellitus. Multiple mechanisms have been proposed, including polyol pathway activation, advanced glycosylation end-product formation, and vasculopathic changes. Nevertheless, specific treatment modalities addressing these basic issues are still lacking. The mainstay of treatment includes pharmacological management with antidepressants, anticonvulsants, and opioids, but these drugs are often limited by unfavorable side-effect profiles. For over 30 years, spinal cord stimulation (SCS) has been used extensively for the management of various chronic neuropathic pain states. In the past decade, interest in the use of SCS for treatment of PDPN has increased. This article reviews pathophysiological mechanisms of PDPN, proposed mechanisms of SCS, and the role of SCS for the treatment of PDPN.
Literature
1.
go back to reference Wild S, Roglic G, Green A, et al. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.PubMedCrossRef Wild S, Roglic G, Green A, et al. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.PubMedCrossRef
2.
go back to reference Zhao Y, Ye W, Boye KS, et al. Healthcare charges and utilization associated with diabetic neuropathy: impact of Type 1 diabetes and presence of other diabetes-related complications and comorbidities. Diabet Med. 2009;26:61–9.PubMedCrossRef Zhao Y, Ye W, Boye KS, et al. Healthcare charges and utilization associated with diabetic neuropathy: impact of Type 1 diabetes and presence of other diabetes-related complications and comorbidities. Diabet Med. 2009;26:61–9.PubMedCrossRef
3.
go back to reference • American Diabetes Association: Economic cost of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596–615. This article provides a very comprehensive overview of the cost of care for diabetes and diabetes-related comorbidities throughout the entire continuum of the health care system. • American Diabetes Association: Economic cost of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596–615. This article provides a very comprehensive overview of the cost of care for diabetes and diabetes-related comorbidities throughout the entire continuum of the health care system.
4.
go back to reference Daousi C, Benbow SJ, Woodward A, et al. The natural history of chronic painful diabetic neuropathy in a community diabetes population. Diabet Med. 2006;23:1021–4.PubMedCrossRef Daousi C, Benbow SJ, Woodward A, et al. The natural history of chronic painful diabetic neuropathy in a community diabetes population. Diabet Med. 2006;23:1021–4.PubMedCrossRef
5.
go back to reference Boulton AJ, Drury J, Clarke B, et al. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care. 1982;5:386–90.PubMedCrossRef Boulton AJ, Drury J, Clarke B, et al. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care. 1982;5:386–90.PubMedCrossRef
6.
go back to reference Oyibo SO, Prasad YD, Jackson NJ, et al. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med. 2002;19:870–3.PubMedCrossRef Oyibo SO, Prasad YD, Jackson NJ, et al. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med. 2002;19:870–3.PubMedCrossRef
7.
go back to reference Podwall D, Gooch C. Diabetic neuropathy: clinical features, etiology and therapy. Curr Neurol Neurosci Rep. 2004;4:55–61.PubMedCrossRef Podwall D, Gooch C. Diabetic neuropathy: clinical features, etiology and therapy. Curr Neurol Neurosci Rep. 2004;4:55–61.PubMedCrossRef
8.
9.
go back to reference Kihara M, Mitsui Y, Shioyama M, et al. Effect of zenarestst, an aldose reductase inhibitor, on endoneurial blood flow in experimental diabetic neuropathy of rat. Neurosci Lett. 2001;310:81–4.PubMedCrossRef Kihara M, Mitsui Y, Shioyama M, et al. Effect of zenarestst, an aldose reductase inhibitor, on endoneurial blood flow in experimental diabetic neuropathy of rat. Neurosci Lett. 2001;310:81–4.PubMedCrossRef
10.
go back to reference Krendal DA: Diabetic neuropathies. In Neuromuscular Function and Disease: Basic Clinical and Electrodiagnositc Aspects. Edited by Brown WE, Bolton CE, Aminoff MD. Philadelphia: WB Suanders; 2002:1061–80. Krendal DA: Diabetic neuropathies. In Neuromuscular Function and Disease: Basic Clinical and Electrodiagnositc Aspects. Edited by Brown WE, Bolton CE, Aminoff MD. Philadelphia: WB Suanders; 2002:1061–80.
11.
go back to reference The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetic therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122:561–8. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetic therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122:561–8.
12.
go back to reference Thomalley PJ. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol. 2002;50:37–50.CrossRef Thomalley PJ. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol. 2002;50:37–50.CrossRef
13.
go back to reference Cameron NE, Eaton S, Cotter MA, et al. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001;44:1973–88.PubMedCrossRef Cameron NE, Eaton S, Cotter MA, et al. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001;44:1973–88.PubMedCrossRef
14.
go back to reference Hall KE, Liu J, Sima AA, et al. Impaired inhibitory G-protein function contributes to increased calcium currents in rats with diabetic neuropathy. J Neurophysiol. 2001;86:760–70.PubMed Hall KE, Liu J, Sima AA, et al. Impaired inhibitory G-protein function contributes to increased calcium currents in rats with diabetic neuropathy. J Neurophysiol. 2001;86:760–70.PubMed
15.
go back to reference Shah BS, Gonzales MI, Bramwell S, et al. β3, a novel auxiliary subunit for the voltage gated sodium channel is upregulated in sensory neurones following streptozocin induced diabetic neuropathy in rat. Neurosci Lett. 2001;309:1–4.PubMedCrossRef Shah BS, Gonzales MI, Bramwell S, et al. β3, a novel auxiliary subunit for the voltage gated sodium channel is upregulated in sensory neurones following streptozocin induced diabetic neuropathy in rat. Neurosci Lett. 2001;309:1–4.PubMedCrossRef
16.
go back to reference Novella SP, Inzucchi SE, Goldstein JM, et al. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve. 2001;24:1229–31.PubMedCrossRef Novella SP, Inzucchi SE, Goldstein JM, et al. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve. 2001;24:1229–31.PubMedCrossRef
17.
go back to reference Summer CJ, Sheth S, Griffith JW, et al. The spectrum of neuropathy in diabetes and glucose tolerance. Neurology. 2003;60:108–11. Summer CJ, Sheth S, Griffith JW, et al. The spectrum of neuropathy in diabetes and glucose tolerance. Neurology. 2003;60:108–11.
18.
go back to reference Partanen J, Niskansen L, Lehtinen J, et al. Natural history of peripheral neuropathy in patients with non-insulin dependent diabetes mellitus. N Engl J Med. 1995;333:89–94.PubMedCrossRef Partanen J, Niskansen L, Lehtinen J, et al. Natural history of peripheral neuropathy in patients with non-insulin dependent diabetes mellitus. N Engl J Med. 1995;333:89–94.PubMedCrossRef
19.
go back to reference Polydefkis M, Hauer P, Griffin JW, et al. Skin biopsy as a tool to assess distal small fiber innervations in diabetic neuropathy. Diabetes Technol Ther. 2001;3:23–8.PubMedCrossRef Polydefkis M, Hauer P, Griffin JW, et al. Skin biopsy as a tool to assess distal small fiber innervations in diabetic neuropathy. Diabetes Technol Ther. 2001;3:23–8.PubMedCrossRef
20.
go back to reference • Kilpatrick ES, Rigby AS, Atkin SL: The Diabetic Control and Complications Trial: the gift that keeps giving. Nat Rev Endocrinol 2009;5:537–45. This thorough review of the background and data to date of the Diabetic Control and Complications Trial provides valuable data from a cohort studied for over a quarter of a century, with detailed information on relationship of glycemic control and the entire spectrum of diabetic complications. • Kilpatrick ES, Rigby AS, Atkin SL: The Diabetic Control and Complications Trial: the gift that keeps giving. Nat Rev Endocrinol 2009;5:537–45. This thorough review of the background and data to date of the Diabetic Control and Complications Trial provides valuable data from a cohort studied for over a quarter of a century, with detailed information on relationship of glycemic control and the entire spectrum of diabetic complications.
21.
go back to reference Hurley RW, Lesley MR, Adams MC, Brummett CM, Wu CL. Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis. Reg Anesth Pain Med. 2008;33:389–94.PubMed Hurley RW, Lesley MR, Adams MC, Brummett CM, Wu CL. Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis. Reg Anesth Pain Med. 2008;33:389–94.PubMed
22.
go back to reference • Ziegler D: Painful diabetic neuropathy: advantage of novel drugs over old drugs? Diabetes Care 2009;32 Suppl 2:S414-9. This is an excellent review of the pharmacological therapeutic options for the treatment of PDPN. Detailed information on the numbers needed to treat and harm allows for data-driven therapy for PDPN. • Ziegler D: Painful diabetic neuropathy: advantage of novel drugs over old drugs? Diabetes Care 2009;32 Suppl 2:S414-9. This is an excellent review of the pharmacological therapeutic options for the treatment of PDPN. Detailed information on the numbers needed to treat and harm allows for data-driven therapy for PDPN.
23.
go back to reference Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324–34.PubMedCrossRef Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324–34.PubMedCrossRef
24.
go back to reference Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the anti-oxidant α-lipoic acid: a meta-analysis. Diabet Med. 2004;21:114–21.PubMedCrossRef Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the anti-oxidant α-lipoic acid: a meta-analysis. Diabet Med. 2004;21:114–21.PubMedCrossRef
25.
go back to reference Zeigler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29:2365–70.CrossRef Zeigler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29:2365–70.CrossRef
27.
go back to reference El-Khoury C, Hawwa M, Baliki M, et al. Attenuation of neuropathic pain by segmental and supraspinal activation of the dorsal column system in awake rats. Neuroscience. 2002;112:541–53.PubMedCrossRef El-Khoury C, Hawwa M, Baliki M, et al. Attenuation of neuropathic pain by segmental and supraspinal activation of the dorsal column system in awake rats. Neuroscience. 2002;112:541–53.PubMedCrossRef
28.
go back to reference • Wu M, Linderoth B, Foreman RD: Putative mechanism behind effects of spinal cord stimulation on vascular diseases: a review of experimental studies. Auton Neurosci 2008;138:9–23. This is an excellent article to read for a clear understanding of the effects of SCS on the CVS through the sympathetic system. Diagrams and layout allow for a clear understanding of the science. • Wu M, Linderoth B, Foreman RD: Putative mechanism behind effects of spinal cord stimulation on vascular diseases: a review of experimental studies. Auton Neurosci 2008;138:9–23. This is an excellent article to read for a clear understanding of the effects of SCS on the CVS through the sympathetic system. Diagrams and layout allow for a clear understanding of the science.
29.
go back to reference Croom JE, Foreman RD, Chandler MJ, et al. Cutaneous vasodilatation during dorsal column stimulation is mediated by dorsal roots and CGRP. Am J Physiol. 1997;272:H950–7.PubMed Croom JE, Foreman RD, Chandler MJ, et al. Cutaneous vasodilatation during dorsal column stimulation is mediated by dorsal roots and CGRP. Am J Physiol. 1997;272:H950–7.PubMed
30.
go back to reference Goksel HM, Karadag O, Turaclar U, et al. Nitric oxide synthetase inhibition attenuates vasoactive response to spinal cord stimulation in an experimental model. Acta Neurochir (Wien). 2001;143:383–90.CrossRef Goksel HM, Karadag O, Turaclar U, et al. Nitric oxide synthetase inhibition attenuates vasoactive response to spinal cord stimulation in an experimental model. Acta Neurochir (Wien). 2001;143:383–90.CrossRef
31.
go back to reference Wu M, Komori N, Qin C, et al. Sensory fibers containing vanilliod receptor-1 (VR-1) mediate spinal cord stimulation-induced vasodilatation. Brain Res. 2006;1107:177–84.PubMedCrossRef Wu M, Komori N, Qin C, et al. Sensory fibers containing vanilliod receptor-1 (VR-1) mediate spinal cord stimulation-induced vasodilatation. Brain Res. 2006;1107:177–84.PubMedCrossRef
32.
go back to reference Wu M, Komori N, Qin C, et al. Extracellular signal regulated kinase (ERK) and protein kinase B (AKT) pathways involved in spinal cord stimulation (SCS)-induced vasodilatation. Brain Res. 2008;207:73–83.CrossRef Wu M, Komori N, Qin C, et al. Extracellular signal regulated kinase (ERK) and protein kinase B (AKT) pathways involved in spinal cord stimulation (SCS)-induced vasodilatation. Brain Res. 2008;207:73–83.CrossRef
33.
go back to reference • Prager JP: What does the mechanism of spinal cord stimulation tell us about complex regional pain syndrome? Pain Med 2010;11:1278–83. This is an excellent review of how the mechanism of action of SCS informs the understanding of the neuropathic pain conditions, complex regional pain syndrome in particular. • Prager JP: What does the mechanism of spinal cord stimulation tell us about complex regional pain syndrome? Pain Med 2010;11:1278–83. This is an excellent review of how the mechanism of action of SCS informs the understanding of the neuropathic pain conditions, complex regional pain syndrome in particular.
34.
go back to reference Stiller CO, Cui JG, O’Connor WT, et al. Release of gamma-aminobutyric acid in the dorsal horn and the suppression of tactile allodynia by spinal cord stimulation in mononeuropathic rats. Neurosurgery. 1996;39:367–74.PubMedCrossRef Stiller CO, Cui JG, O’Connor WT, et al. Release of gamma-aminobutyric acid in the dorsal horn and the suppression of tactile allodynia by spinal cord stimulation in mononeuropathic rats. Neurosurgery. 1996;39:367–74.PubMedCrossRef
35.
go back to reference Schectmann G, Song Z, Ulitenius C, et al. Cholinergic mechanisms involved in pain relieving effect of spinal cord stimulation in a model of neuropathy. Pain. 2008;139:136–45.CrossRef Schectmann G, Song Z, Ulitenius C, et al. Cholinergic mechanisms involved in pain relieving effect of spinal cord stimulation in a model of neuropathy. Pain. 2008;139:136–45.CrossRef
36.
go back to reference Linderoth B, Stiller CO, Gunasekera L, et al. Gamma-aminobutyric acid is released in the dorsal horn by electrical spinal cord stimulation: an in vivo microdialysis study in the rat. Neurosurgery. 1994;34:484–8.PubMedCrossRef Linderoth B, Stiller CO, Gunasekera L, et al. Gamma-aminobutyric acid is released in the dorsal horn by electrical spinal cord stimulation: an in vivo microdialysis study in the rat. Neurosurgery. 1994;34:484–8.PubMedCrossRef
37.
go back to reference Tesfaye S, Watt J, Benbow SJ, et al. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet. 1996;348:1698–701.PubMedCrossRef Tesfaye S, Watt J, Benbow SJ, et al. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet. 1996;348:1698–701.PubMedCrossRef
38.
go back to reference Daousi C, Benbow SJ, MacFarlane IA. Electrical stimulation in the long-term treatment of chronic painful diabetic neuropathy. Diabet Med. 2005;22:393–8.PubMedCrossRef Daousi C, Benbow SJ, MacFarlane IA. Electrical stimulation in the long-term treatment of chronic painful diabetic neuropathy. Diabet Med. 2005;22:393–8.PubMedCrossRef
39.
go back to reference de Vos CC, Rajan V, Steenbergen W, et al. Effect and safety of spinal cord stimulation for the treatment of chronic pain caused by diabetic neuropathy. J Diabetes Complications. 2009;23:40–5.PubMedCrossRef de Vos CC, Rajan V, Steenbergen W, et al. Effect and safety of spinal cord stimulation for the treatment of chronic pain caused by diabetic neuropathy. J Diabetes Complications. 2009;23:40–5.PubMedCrossRef
40.
go back to reference Kapural L, Hayek S, Stanton-Hicks M, et al. Decreased insulin requirements with spinal cord stimulation in a patient with diabetes. Anesth Analg. 2004;98:745–6.PubMedCrossRef Kapural L, Hayek S, Stanton-Hicks M, et al. Decreased insulin requirements with spinal cord stimulation in a patient with diabetes. Anesth Analg. 2004;98:745–6.PubMedCrossRef
41.
go back to reference Jeon JY, Weiss CB, Steadward RD, et al. Improved glucose tolerance and insulin sensitivity after electrical stimulation-assisted cycling in people with spinal cord injury. Spinal Cord. 2002;40:110–7.PubMedCrossRef Jeon JY, Weiss CB, Steadward RD, et al. Improved glucose tolerance and insulin sensitivity after electrical stimulation-assisted cycling in people with spinal cord injury. Spinal Cord. 2002;40:110–7.PubMedCrossRef
Metadata
Title
Contemporary Insights into Painful Diabetic Neuropathy and Treatment with Spinal Cord Stimulation
Authors
Kai McGreevy
Kayode A. Williams
Publication date
01-02-2012
Publisher
Current Science Inc.
Published in
Current Pain and Headache Reports / Issue 1/2012
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-011-0230-2

Other articles of this Issue 1/2012

Current Pain and Headache Reports 1/2012 Go to the issue

Chronic Daily Headache (SJ Wang, Section Editor)

Defining the Differences Between Episodic Migraine and Chronic Migraine

Anesthetic Techniques in Pain Management (GJ Brenner, Section Editor)

Radiofrequency Treatment of Facet-related Pain: Evidence and Controversies

Chronic Daily Headache (SJ Wang, Section Editor)

Obesity and Chronic Daily Headache

Chronic Daily Headache (SJ Wang, Section Editor)

Cortical Excitability in Chronic Migraine

Anesthetic Techniques in Pain Management (GJ Brenner, Section Editor)

Epidural Steroid Injections